Terms: = Prostate cancer AND MYCL, LMYC, 4610, MYCL1, ENSG00000116990
13 results:
1. Daily physical activity monitoring in older adults with metastatic prostate cancer on active treatment: Feasibility and associations with toxicity.
Feng G; Parthipan M; Breunis H; Timilshina N; Soto-Perez-de-Celis E; Mina DS; Emmenegger U; Finelli A; Krzyzanowska MK; Clarke H; Puts M; Alibhai SMH
J Geriatr Oncol; 2023 Sep; 14(7):101576. PubMed ID: 37421787
[TBL] [Abstract] [Full Text] [Related]
2. Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers.
Pereira-Veiga T; González-Conde M; León-Mateos L; Piñeiro-Cid R; Abuín C; Muinelo-Romay L; Martínez-Fernández M; Brea Iglesias J; García González J; Anido U; Aguín-Losada S; Cebey V; Costa C; López-López R
Clin Exp Metastasis; 2021 Apr; 38(2):239-251. PubMed ID: 33635497
[TBL] [Abstract] [Full Text] [Related]
3. Regional differences in total hospital charges between open and robotically assisted radical prostatectomy in the United States.
Preisser F; Nazzani S; Mazzone E; Knipper S; Bandini M; Tian Z; Haese A; Saad F; Zorn KC; Montorsi F; Shariat SF; Graefen M; Tilki D; Karakiewicz PI
World J Urol; 2019 Jul; 37(7):1305-1313. PubMed ID: 30315358
[TBL] [Abstract] [Full Text] [Related]
4. Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical prostatectomy.
Tosoian JJ; Almutairi F; Morais CL; Glavaris S; Hicks J; Sundi D; Humphreys E; Han M; De Marzo AM; Ross AE; Tomlins SA; Schaeffer EM; Trock BJ; Lotan TL
Eur Urol; 2017 May; 71(5):697-700. PubMed ID: 27477529
[TBL] [Abstract] [Full Text] [Related]
5. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant prostate cancer.
Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
[TBL] [Abstract] [Full Text] [Related]
7. Spatial genomic heterogeneity within localized, multifocal prostate cancer.
Boutros PC; Fraser M; Harding NJ; de Borja R; Trudel D; Lalonde E; Meng A; Hennings-Yeomans PH; McPherson A; Sabelnykova VY; Zia A; Fox NS; Livingstone J; Shiah YJ; Wang J; Beck TA; Have CL; Chong T; Sam M; Johns J; Timms L; Buchner N; Wong A; Watson JD; Simmons TT; P'ng C; Zafarana G; Nguyen F; Luo X; Chu KC; Prokopec SD; Sykes J; Dal Pra A; Berlin A; Brown A; Chan-Seng-Yue MA; Yousif F; Denroche RE; Chong LC; Chen GM; Jung E; Fung C; Starmans MH; Chen H; Govind SK; Hawley J; D'Costa A; Pintilie M; Waggott D; Hach F; Lambin P; Muthuswamy LB; Cooper C; Eeles R; Neal D; Tetu B; Sahinalp C; Stein LD; Fleshner N; Shah SP; Collins CC; Hudson TJ; McPherson JD; van der Kwast T; Bristow RG
Nat Genet; 2015 Jul; 47(7):736-45. PubMed ID: 26005866
[TBL] [Abstract] [Full Text] [Related]
8. prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death.
Shi Z; Pinnock CB; Kinsey-Trotman S; Borg M; Moretti KL; Walsh S; Kopsaftis T
Radiother Oncol; 2013 May; 107(2):129-33. PubMed ID: 23623726
[TBL] [Abstract] [Full Text] [Related]
9. Genetic variant as a selection marker for anti-prostate stem cell antigen immunotherapy of bladder cancer.
Kohaar I; Porter-Gill P; Lenz P; Fu YP; Mumy A; Tang W; Apolo AB; Rothman N; Baris D; Schned AR; Ylaya K; Schwenn M; Johnson A; Jones M; Kida M; Silverman DT; Hewitt SM; Moore LE; Prokunina-Olsson L
J Natl Cancer Inst; 2013 Jan; 105(1):69-73. PubMed ID: 23266392
[TBL] [Abstract] [Full Text] [Related]
10. Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial.
Rodriguez RF; Bravo LE; Castro F; Montoya O; Castillo JM; Castillo MP; Daza P; Restrepo JM; Rodriguez MF
J Palliat Med; 2007 Feb; 10(1):56-60. PubMed ID: 17298254
[TBL] [Abstract] [Full Text] [Related]
11. Gene amplifications associated with the development of hormone-resistant prostate cancer.
Edwards J; Krishna NS; Witton CJ; Bartlett JM
Clin Cancer Res; 2003 Nov; 9(14):5271-81. PubMed ID: 14614009
[TBL] [Abstract] [Full Text] [Related]
12. Microsatellite instability of dinucleotide tandem repeat sequences is higher than trinucleotide, tetranucleotide and pentanucleotide repeat sequences in prostate cancer.
Perinchery G; Nojima D; Goharderakhshan R; Tanaka Y; Alonzo J; Dahiya R
Int J Oncol; 2000 Jun; 16(6):1203-9. PubMed ID: 10811996
[TBL] [Abstract] [Full Text] [Related]
13. Restriction fragment length polymorphism of the L-myc gene and susceptibility to metastasis in genitourinary cancers.
Kakehi Y; Taki Y; Yoshida O
Urol Int; 1991; 47 Suppl 1():86-9. PubMed ID: 1683040
[TBL] [Abstract] [Full Text] [Related]
